TB Resources
Resources for Health Care Providers
*Suspected or confirmed active tuberculosis disease is a reportable condition in Alaska.*
Cases should be reported to the Alaska TB Program within 2 business days. Please call
the Section of Epidemiology at 907-269-8000, or complete the appropriate report form and fax to 907-561-4239.
*NOTICE of PRIFTIN® (RIFAPENTINE) impurity issue 7-1-20*
In
June 2020 Sanofi alerted the Division of Tuberculosis Elimination, other health
agencies, and stakeholders worldwide about a newly detected impurity in
Priftin®. The impurity, 1-cyclopentyl-4-nitrosopiperazine, is a nitrosamine and
a potential carcinogen. Read more at the links below.
Letter to Alaska providers/public health nurses
Information from CDC
Provider Toolkit
Screening/Assessment
The USPSTF recommends
screening for latent TB infection (LTBI) in populations at increased
risk. Finding and treating patients with LTBI is key to controlling the
TB epidemic.
Testing/Diagnosis
IGRA (blood) testing is now
approved for all persons>2 years of age and has some advantages over
TST (skin test), especially in foreign-born persons who may have
received BCG vaccination in the past.
Treatment for LTBI
There are now shorter-course
regimens which make LTBI treatment easier. It is very important to rule
out active TB disease prior to starting treatment for LTBI.
Treatment for Active TB
Patient Education
Training/Resources
For Civil Surgeons
Webinars